To determine whether ZOL/IL-2 regimen could activate and expand Vγ2Vδ2 T cells in high-dose MDR-TB infection, the 1st administration (Table 1) began at week 1 (day 7) after infection, and was assessed for increases in percentages and absolute numbers of Vγ2Vδ2 T cells. The gene discussed is IL2; the disease is infection.